國立虎尾科技大學 |

Ketamine for Treatment-Resistant Depression = The First Decade of Progress /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Ketamine for Treatment-Resistant Depression/ edited by Sanjay J. Mathew, Carlos A. Zarate, Jr.
Reminder of title:	The First Decade of Progress /
other author:	Mathew, Sanjay J.
Description:	XIX, 155 p. 6 illus., 3 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Psychopharmacology. -
Online resource:	https://doi.org/10.1007/978-3-319-42925-0
ISBN:	9783319429250

Ketamine for Treatment-Resistant Depression = The First Decade of Progress /
Ketamine for Treatment-Resistant DepressionThe First Decade of Progress /[electronic resource] :edited by Sanjay J. Mathew, Carlos A. Zarate, Jr. - 1st ed. 2016. - XIX, 155 p. 6 illus., 3 illus. in color.online resource.

1. History of Ketamine Use and its Clinical Indications -- 2. Basic and Clinical Pharmacology of Ketamine -- 3. Ketamine: Clinical Studies in Treatment-Resistant Depressive Disorders -- 4. Ketamine and Suicidality -- 5. Ketamine: Safety, Tolerability, and Impact on Neurocognition -- 6. Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence Gleaned from Pre-Clinical Studies -- 7. Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies -- 8. Ketamine and Electroconvulsive Therapy -- 9. Beyond Depressive Disorders: Emerging Data for the Use of Ketamine in OCD, PTSD, and Alcohol/Substance Use Disorders.

This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine’s psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine’s rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine’s rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research. .

ISBN: 9783319429250

Standard No.: 10.1007/978-3-319-42925-0doiSubjects--Topical Terms:

644799
Psychopharmacology.

LC Class. No.: RM315-334

Dewey Class. No.: 615.78

Ketamine for Treatment-Resistant Depression = The First Decade of Progress /
LDR:04192nam a22003975i 4500 001 980473
003 DE-He213
005 20200702072434.0
007 cr nn 008mamaa
008 201211s2016 gw | s |||| 0|eng d
020 $a 9783319429250 $9 978-3-319-42925-0
024 7 $a 10.1007/978-3-319-42925-0 $2 doi
035 $a 978-3-319-42925-0
050 4 $a RM315-334
072 7 $a MMGW $2 bicssc
072 7 $a MED105020 $2 bisacsh
072 7 $a MKGW $2 thema
082 0 4 $a 615.78 $2 23
245 1 0 $a Ketamine for Treatment-Resistant Depression $h [electronic resource] : $b The First Decade of Progress / $c edited by Sanjay J. Mathew, Carlos A. Zarate, Jr.
250 $a 1st ed. 2016.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Adis, $c 2016.
300 $a XIX, 155 p. 6 illus., 3 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a 1. History of Ketamine Use and its Clinical Indications -- 2. Basic and Clinical Pharmacology of Ketamine -- 3. Ketamine: Clinical Studies in Treatment-Resistant Depressive Disorders -- 4. Ketamine and Suicidality -- 5. Ketamine: Safety, Tolerability, and Impact on Neurocognition -- 6. Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence Gleaned from Pre-Clinical Studies -- 7. Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies -- 8. Ketamine and Electroconvulsive Therapy -- 9. Beyond Depressive Disorders: Emerging Data for the Use of Ketamine in OCD, PTSD, and Alcohol/Substance Use Disorders.
520 $a This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine’s psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine’s rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine’s rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research. .
650 0 $a Psychopharmacology. $3 644799
700 1 $a Mathew, Sanjay J. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1115875
700 1 $a Zarate, Jr., Carlos A. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1273256
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319429236
776 0 8 $i Printed edition: $z 9783319429243
776 0 8 $i Printed edition: $z 9783319826950
856 4 0 $u https://doi.org/10.1007/978-3-319-42925-0
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)